Open randomized multinational phase IIIb trial evaluating the activity and safety of cetuximab as 250 mg m weekly and 500 mg m every two weeks maintenance therapy after platinum based chemotherapy in combination with cetuximab as first line treatment for subjects with advanced non small cell lung cancer NSCLC